Order Article Reprints

Mokbel S, Baciarello G, Lavaud P, Omlin A, Calabrò F, Cathomas R, Aeppli S, Parent P, Giannatempo P, Koster K-L, et al. Development and Validation of an Inflammatory Prognostic Index to Predict Outcomes in Advanced/Metastatic Urothelial Cancer Patients Receiving Immune Checkpoint Inhibitors. Cancers. 2024; 16(8):1465. https://doi.org/10.3390/cancers16081465

Mokbel, Sara, Giuilia Baciarello, Pernelle Lavaud, Aurelius Omlin, Fabio Calabrò, Richard Cathomas, Stefanie Aeppli, Pauline Parent, Patrizia Giannatempo, Kira-Lee Koster, and et al. 2024. "Development and Validation of an Inflammatory Prognostic Index to Predict Outcomes in Advanced/Metastatic Urothelial Cancer Patients Receiving Immune Checkpoint Inhibitors" Cancers 16, no. 8: 1465. https://doi.org/10.3390/cancers16081465

Mokbel, S., Baciarello, G., Lavaud, P., Omlin, A., Calabrò, F., Cathomas, R., Aeppli, S., Parent, P., Giannatempo, P., Koster, K.-L., Appel, N., Gonnet, P., Angius, G., Tsantoulis, P., Arkenau, H.-T., Cattrini, C., Messina, C., Zeghondy, J., Morelli, C., ... Patrikidou, A. (2024). Development and Validation of an Inflammatory Prognostic Index to Predict Outcomes in Advanced/Metastatic Urothelial Cancer Patients Receiving Immune Checkpoint Inhibitors. Cancers, 16(8), 1465. https://doi.org/10.3390/cancers16081465